期刊文献+

CT导引下^(125)I粒子植入在治疗恶性肿瘤中的应用 被引量:135

CT-guided percutaneous permanent ^(125)I implantation for patients with malignant tumor
原文传递
导出
摘要 目的 评价CT导引下瘤体内12 5I粒子植入治疗恶性肿瘤的可行性、安全性及其疗效。方法  10例 13个病灶行CT导引下瘤体内12 5I粒子植入 ,其中原发肿瘤 4例 ,转移瘤 6例 (9个病灶 )。患者男 4例 ,女 6例 ,年龄 5 4~ 6 2岁 (平均 5 6 .9岁 )。依据粒子植入术前 15d内CT图像应用计算机治疗计划系统制定粒子植入计划 ,按治疗计划在CT导引下穿刺植入12 5I粒子。植入术后立即CT扫描及术后 5~ 10个月CT扫描观察粒子在瘤体内的分布、有无并发症发生及疗效。结果  10例粒子植入均顺利完成 ,粒子分布满意 ,单个瘤体内植入12 5I粒子数为 1~ 4 4粒 (平均 18.6粒 )。未见急性并发症和治疗相关的放射损伤。全部 4例疼痛患者粒子植入术后疼痛均有明显减轻。随诊CT检查示 3个病灶消失 ,8个病灶明显缩小 ,其余 2个病灶大小无明显变化。植入术前及植入术后随诊显示病灶平均大小分别为 3.15和 2 .0 6cm(t =5 .12 7,P <0 .0 0 1)。结论 CT导引下12 5I粒子植入近距离放射治疗对原发及转移性恶性肿瘤是 1种安全、可行、有效的治疗方法在恶性肿瘤的治疗中外照射起着重要作用 ,但由于外照射放疗的准确性较差 ,对周围正常组织损伤明显 ,效果常常不太理想。病灶内放射性粒子植入近距离治疗恶性肿瘤是 1种新的放疗手段 。 Objective To evaluate the feasibility, safety, and efficacy of CT-guided permanent iodine-125 implantation for malignant tumors.Methods Thirteen lesions in 10 consecutive patients with malignant tumor were treated with CT-guided iodine-125 permanent implantation brachytherapy, of which four cases were primary unresectable carcinoma and six cases were metastases. There were 4 males and (6 females,) the mean age was 56.9 years (range 54 to 62 years). Based on the CT imaging within two weeks before the implantation of the seeds, a computer-based treatment planning system was used to determine the optimal seed distribution. Subsequent CT-guided needle placement and seed implantation were carried out. Post-implant CT scans were performed immediately and five to ten months after the implantation in all cases to assess seed distribution, complication, and curative effect. Results CT-guided iodine-125 permanent implantation was accomplished smoothly in all cases. This technique offered a better seed placement. The number of seeds implanted in one lesion was 1 to 44 (mean 18.6). No acute complications and late toxicity related to the implantation were observed. Pain relief was obtained in all four patients (100%) presenting with pain. Follow-up CT demonstrated that 3 of 13 lesions disappeared completely, eight lesions diminished, and the remaining 2 lesions had no significant change in size. Mean lesion size of pre-implant and post-implant were 3.15 cm and 2.06 cm, respectively (t=5.127, P<0.001). Conclusion CT-guided iodine-125 permanent implantation is a feasible, effective, and safe method in the treatment of both primary unresectable carcinoma and metastases.
出处 《中华放射学杂志》 CAS CSCD 北大核心 2004年第9期921-925,共5页 Chinese Journal of Radiology
关键词 ^125I粒子 CT导引 植入 病灶 治疗 瘤体 体内 计算机 显示 大小 Neoplasms by site Iodine radioisotopes Radiology, interventional Brachytherapy
  • 相关文献

参考文献12

  • 1Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys,2000,47:1261-1266.
  • 2Willins J, Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys,1997,39:347-353.
  • 3Molloy JA, Williams MB. Treatment planning considerations and quality assurance for CT-guided transischiorectal implantation of the prostate. Med Phys,1999,26:1943-1951.
  • 4Martinez-Monge R, Nag S, Nieroda CA, et al. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer,1999,85:1218-1225.
  • 5Vikram B, Mishra S.Permanent iodine-125 implants in postoperative radiotherapy for head and neck cancer with positive surgical margins. Head Neck,1994,16:155-157.
  • 6Kumar PP, Patil AA, Leibrock LG,et al. Continuous low dose rate brachytherapy with high activity iodine-125 seeds in the management of meningiomas. Int J Radiat Oncol Biol Phys,1993,25:325-328.
  • 7Lee DJ, Liberman FZ, Park RI, et al. Intraoperative I-125 seed implantation for extensive recurrent head and neck carcinomas. Radiology,1991,178:879-882.
  • 8Heelan RT, Hilaris BS, Anderson LL, et al. Lung tumors: percutaneous implantation of I-125 sources with CT treatment planning. Radiology, 1987,164:735-740.
  • 9Lee W, Daly BD, DiPetrillo TA, et al. Limited resection for non-small cell lung cancer: observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg,2003,75:237-243.
  • 10Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys, 2003,56:1085-1092.

同被引文献719

引证文献135

二级引证文献771

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部